(Q47322152)

English

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy

scientific article published on 7 December 2017

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy (English)

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Peter A. Fasching

20

object named as

Peter A Fasching

1 reference

Europe PubMed Central

14 January 2018

Andreas Schneeweiss

17

object named as

Andreas Schneeweiss

1 reference

Europe PubMed Central

14 January 2018

27

object named as

Sibylle Loibl

1 reference

Europe PubMed Central

14 January 2018

26

object named as

Michael Untch

1 reference

Europe PubMed Central

14 January 2018

18

object named as

Arndt Hartmann

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

author name string

Carsten Denkert

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Gunter von Minckwitz

2

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Silvia Darb-Esfahani

3

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Bianca Lederer

4

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Barbara I Heppner

5

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Karsten E Weber

6

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Jan Budczies

7

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Jens Huober

8

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Frederick Klauschen

9

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Jenny Furlanetto

10

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Wolfgang D Schmitt

11

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Jens-Uwe Blohmer

12

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Thomas Karn

13

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Berit M Pfitzner

14

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Sherko Kümmel

15

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Knut Engels

16

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Aurelia Noske

19

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Christian Jackisch

21

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Marion van Mackelenbergh

22

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Peter Sinn

23

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Christian Schem

24

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Claus Hanusch

25

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

publication date

7 December 2017

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Lancet Oncology Commission

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

19

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

1

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

40-50

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Tumor-associated lymphocytes as an independent predictor of response to neoadjuvant chemotherapy in breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Clinical relevance of host immunity in breast cancer: from TILs to the clinic

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Doxorubicin with cyclophosphamide followed by docetaxel every 21 days compared with doxorubicin and docetaxel every 14 days as preoperative treatment in operable breast cancer: the GEPARDUO study of the German Breast Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Response-guided neoadjuvant chemotherapy for breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine in addition to anthracycline- and taxane-based neoadjuvant treatment in patients with primary breast cancer: phase III GeparQuattro study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prospective validation of immunological infiltrate for prediction of response to neoadjuvant chemotherapy in HER2-negative breast cancer--a substudy of the neoadjuvant GeparQuinto trial

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Tumor-infiltrating lymphocytes and response to neoadjuvant chemotherapy with or without carboplatin in human epidermal growth factor receptor 2-positive and triple-negative primary breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Reporting recommendations for tumor marker prognostic studies (REMARK).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Neoadjuvant chemotherapy shows similar response in patients with inflammatory or locally advanced breast cancer when compared with operable breast cancer: a secondary analysis of the GeparTrio trial data

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Effect of aromatase inhibition on functional gene modules in estrogen receptor-positive breast cancer and their relationship with antiproliferative response

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Genomic Analysis of Immune Cell Infiltrates Across 11 Tumor Types

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular and genetic properties of tumors associated with local immune cytolytic activity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Molecular anatomy of breast cancer stroma and its prognostic value in estrogen receptor-positive and -negative cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Robust enumeration of cell subsets from tissue expression profiles

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

The prognostic landscape of genes and infiltrating immune cells across human cancers

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Patterns of Immune Infiltration in Breast Cancer and Their Clinical Implications: A Gene-Expression-Based Retrospective Study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Refinement of Triple-Negative Breast Cancer Molecular Subtypes: Implications for Neoadjuvant Chemotherapy Selection.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2817%2930904-X

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(17)30904-X

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

release_dpwfpa7vdnc7bjntbxd66ysunm

1 reference

https://api.fatcat.wiki/v0/release/dpwfpa7vdnc7bjntbxd66ysunm

24 November 2022

based on heuristic

mapped directly with Wikidata item

1 reference

Europe PubMed Central

14 January 2018

http://europepmc.org/abstract/MED/29233559

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q47322152&oldid=2152107562"